Inhibikase Therapeutics raises $10M as disease treatments show success

Atlanta-based pharmaceutical company Inhibikase Therapeutics Inc. (Nasdaq: IKT) has raised $10 million for development of treatments for Parkinson’s Disease and chronic myelogenous leukemia.

The investment included a $4.2 million in a private investment in public equity (PIPE) deal from New York-based Armistice Capital and $5.2 million from a confidentially marketed registered direct offering, said president and CEO Milton Werner. The remaining funds came from banking fees and commissions.


Previous Chapel Hill medtech laying off 48 workers as sell off looms
Next How food incubator Hatch helps grow Richmond's culinary scene